Literature DB >> 3686045

The description of chemotherapy delivery: options and pitfalls.

C M Coppin1.   

Abstract

Delivered and planned drug doses in chemotherapy trials are analyzed in relation to dose size, dose rate, and total drug delivery. Time-dose factors are presented in different ways, further exploring what may be misleading when comparing one treatment program with another. The time frame over which treatment intensity is to be calculated is recognized as arbitrary and not necessarily from start to end of treatment. Considerations for doses missed are presented. The cumulative-dose plot represents a new method of data presentation. This method graphically captures both intensity and total drug delivery per patient, and is helpful when analyzing trials designed to isolate treatment variables and improve the therapeutic index of available drugs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3686045

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  5 in total

Review 1.  Chemotherapy for Hodgkin's disease and aggressive non-Hodgkin's lymphoma. More is better, or is it?

Authors:  D J Dodwell; E S de Campos; J A Radford
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

2.  Continuous versus intermittent prednimustine treatment of non-Hodgkin's lymphoma.

Authors:  T Hatschek; L Baldetorp; J Carstensen; L Håkansson; T Möller; B Nilsson; B Termander
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

Review 3.  Dose intensity in cancer chemotherapy.

Authors:  D J Dodwell; H Gurney; N Thatcher
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

4.  Calculation of received dose intensity for combinations of drugs using small-cell lung carcinoma treatment regimens as examples.

Authors:  G L Wampler; J G Fryer
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  A trial of individual dose intensity and relative performance factors in tegafur maintenance chemotherapy for head and neck cancer.

Authors:  S Sawaki; H Watanabe; T Shin; T Kubota; S Komiyama; T Umezaki; I Nahm
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.